Considering that some genetic alterations in TP53 have previously been reported as gain-of-function, oncogenic mutations [41], it is probable that the role of CDKN1A and p21 may also change from anticancer to cancer-promoting when the TP53-dependent molecular context is aberrated. The gene discussed is TP53; the disease is cancer.